Open AccessPhase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
Author(s) -
Athanassios Argiris,
Michalis V. Karamouzis,
William E. Gooding,
Barton F. Branstetter,
Shilong Zhong,
Luis E. Raez,
P. Savvides,
Marjorie Romkes
Publication year - 2011
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2010.33.3591
Subject(s) - medicine , bevacizumab , pemetrexed , methylenetetrahydrofolate reductase , neutropenia , oncology , antifolate , thymidylate synthase , gastroenterology , vascular endothelial growth factor , chemotherapy , surgery , fluorouracil , antimetabolite , genotype , cisplatin , biochemistry , chemistry , vegf receptors , gene
We hypothesized that bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), will potentiate the activity of pemetrexed, a multitargeted antifolate, in squamous cell carcinoma of the head and neck (SCCHN).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom